AbbVie Inc (ABBV) Can Be Worth $53-78 On Pricing Humira IP: Leerink

AbbVie Inc (ABBV) Can Be Worth $53-78 On Pricing Humira IP: Leerink

Leerink analysts weigh in on different Humira scenarios facing AbbVie


Celgene Corporation (CELG): Leerink Raises PT On Crohn's Drug Data, Delays Launch

Leerink Partners analysts expect GED-0301 to hit the markets by the third quarter of 2019

Johnson & Johnson (JNJ): Street Shrugs Off Pfizer Inc.'s (PFE) Remicade Threat

Analysts weigh in on Johnson and Johnson's prospects as cheaper competition to Remicade looms closer

Credit Suisse Initiates Sarepta Therapeutics Inc (SRPT) With Outperform; Shares Shoot Up

Credit Suisse analysts believe Exondys 51 may only be the beginning for Sarepta

Gilead Sciences, Inc. (GILD): Baird Cuts Price Target On Possible Q3 Miss

Baird analysts lower third quarter estimates for Gilead based on HCV script data

Will Pfizer Inc.'s (PFE) Xeljanz Cure Ulcerative Colitis?

Pfizer has to look for multiple options in order to expand the label expansion of its drugs due to fierce competition

AbbVie Inc (ABBV) A Step Ahead in Leukemia Portfolio

The drug maker has a good window of opportunity to patch up the revenue loss due to patent expiration and biosimilars